|
Mar 4
|
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
|
|
Jan 3
|
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
|
|
Jan 1
|
Positive Signs As Multiple Insiders Buy BioCardia Stock
|
|
Dec 19
|
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
|
|
Dec 18
|
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
|
|
Nov 29
|
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
|
|
Nov 8
|
BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates
|
|
Nov 8
|
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
|
|
Aug 11
|
BioCardia, Inc. (NASDAQ:BCDA) Q2 2023 Earnings Call Transcript
|
|
Aug 9
|
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 9
|
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
|